Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Kwiwan | - |
dc.contributor.author | Chang, JuOae | - |
dc.contributor.author | Park, Sun-mi | - |
dc.contributor.author | Kim, Jinhee | - |
dc.contributor.author | Jeon, Sangeun | - |
dc.contributor.author | Kim, Dong Hwan | - |
dc.contributor.author | Kim, Young-Eui | - |
dc.contributor.author | Lee, Joo Chan | - |
dc.contributor.author | Im, Somyoung | - |
dc.contributor.author | Jo, Yejin | - |
dc.contributor.author | Min, Ji-Young | - |
dc.contributor.author | Lee, Hanbyeul | - |
dc.contributor.author | Yeom, Minjoo | - |
dc.contributor.author | Seok, Sang-Hyuk | - |
dc.contributor.author | On, Da In | - |
dc.contributor.author | Noh, Hyuna | - |
dc.contributor.author | Yun, Jun-Won | - |
dc.contributor.author | Park, Jun Won | - |
dc.contributor.author | Song, Daesub | - |
dc.contributor.author | Seong, Je Kyung | - |
dc.contributor.author | Kim, Kyung-Chang | - |
dc.contributor.author | Lee, Joo-Yeon | - |
dc.contributor.author | Park, Hyun-Ju | - |
dc.contributor.author | Kim, Seungtaek | - |
dc.contributor.author | Nam, Tae-gyu | - |
dc.contributor.author | Lee, Wonsik | - |
dc.date.accessioned | 2023-09-04T05:31:38Z | - |
dc.date.available | 2023-09-04T05:31:38Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 0166-3542 | - |
dc.identifier.issn | 1872-9096 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/114562 | - |
dc.description.abstract | To identify potent antiviral compounds, we introduced a high-throughput screen platform that can rapidly classify hit compounds according to their target. In our platform, we performed a compound screen using a lentivirus-based pseudovirus presenting a spike protein of coronavirus, and we evaluated the hit compounds using an amplified luminescence proximity homogeneous assay (alpha) test with purified host receptor protein and the receptor binding domain of the viral spike. With our screen platform, we were able to identify both spike-specific compounds (class I) and broad-spectrum antiviral compounds (class II). Among the hit compounds, thiosemicarbazide was identified to be selective to the interaction between the viral spike and its host cell receptor, and we further optimized the binding potency of thiosemicarbazide through modification of the pyridine group. Among the class II compounds, we found raloxifene and amiodarone to be highly potent against human coronaviruses including Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-CoV-2. In particular, using analogs of the benzothiophene moiety, which is also present in raloxifene, we have identified benzothiophene as a novel structural scaffold for broad-spectrum antivirals. This work highlights the strong utility of our screen platform using a pseudovirus assay and an alpha test for rapid identi-fication of potential antiviral compounds and their mechanism of action, which can lead to the accelerated development of therapeutics against newly emerging viral infections. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.antiviral.2022.105473 | - |
dc.identifier.scopusid | 2-s2.0-85145614830 | - |
dc.identifier.wosid | 001033570100001 | - |
dc.identifier.bibliographicCitation | Antiviral Research, v.209, pp 1 - 14 | - |
dc.citation.title | Antiviral Research | - |
dc.citation.volume | 209 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | RECEPTOR-BINDING DOMAIN | - |
dc.subject.keywordPlus | MERS-COV | - |
dc.subject.keywordPlus | SARS CORONAVIRUS | - |
dc.subject.keywordPlus | FUNCTIONAL INHIBITORS | - |
dc.subject.keywordPlus | ENTRY | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | AMIODARONE | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | RALOXIFENE | - |
dc.subject.keywordPlus | LIPIDS | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S016635422200242X | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.